The Federal Trade Commission's recent consent orders on generic mergers suggest the antitrust watchdog is concerned with preserving as many competitors as possible. It's been requiring divestures even when multiple competitors would remain on the market after an acquisition.
FTC announced Feb. 26 that Hikma Pharmaceuticals PLC must divest two marketed generic products and rights to a third generic undergoing FDA review to remedy the anticompetitive effects of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?